Evotec SE Share Price

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Real-time Estimate Tradegate 03:47:39 20/06/2024 pm IST 5-day change 1st Jan Change
8.475 EUR +15.54% Intraday chart for Evotec SE +1.02% -60.41%

Financials

Sales 2024 * 883M 946M 79.06B Sales 2025 * 1.04B 1.11B 92.96B Capitalization 1.3B 1.39B 116B
Net income 2024 * -28M -30.01M -2.51B Net income 2025 * 31M 33.23M 2.78B EV / Sales 2024 * 1.73 x
Net Debt 2024 * 227M 243M 20.34B Net Debt 2025 * 186M 200M 16.71B EV / Sales 2025 * 1.43 x
P/E ratio 2024 *
-47 x
P/E ratio 2025 *
27.6 x
Employees 5,055
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+13.70%
1 week-0.72%
Current month-4.33%
1 month-14.51%
3 months-39.58%
6 months-60.53%
Current year-61.09%
More quotes
1 week
7.22
Extreme 7.215
8.65
1 month
7.22
Extreme 7.215
9.79
Current year
7.22
Extreme 7.215
21.42
1 year
7.22
Extreme 7.215
24.44
3 years
7.22
Extreme 7.215
45.83
5 years
7.22
Extreme 7.215
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19/19/19
Director of Finance/CFO 51 07/23/07
Chief Operating Officer 54 01/12/01
Members of the board TitleAgeSince
Chief Executive Officer 61 19/19/19
Director/Board Member 56 19/19/19
Chairman 63 17/14/17
More insiders
Date Price Change Volume
20/24/20 8.425 +14.86% 1 704 816
19/24/19 7.335 -2.65% 598,980
18/24/18 7.535 -0.86% 1,050,669
17/24/17 7.6 -9.52% 4,005,319
14/24/14 8.4 +0.72% 974,254

Delayed Quote Xetra, June 20, 2024 at 02:55 pm IST

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.335 EUR
Average target price
20.79 EUR
Spread / Average Target
+183.44%
Consensus